News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
839,964 Results
Type
Article (86159)
Company Profile (649)
Press Release (753156)
Multimedia
Podcasts (131)
Webinars (14)
Section
Business (232250)
Career Advice (4126)
Deals (39714)
Drug Delivery (126)
Drug Development (90807)
Employer Resources (198)
FDA (18011)
Job Trends (17332)
News (395616)
Policy (39679)
Tag
Academia (2992)
Academic (1)
Accelerated approval (6)
Adcomms (25)
Allergies (82)
Alliances (56678)
ALS (83)
Alzheimer's disease (1474)
Antibody-drug conjugate (ADC) (148)
Approvals (17991)
Artificial intelligence (231)
Autoimmune disease (28)
Automation (12)
Bankruptcy (402)
Best Places to Work (12511)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (447)
Bladder cancer (77)
Brain cancer (26)
Breast cancer (238)
Cancer (2085)
Cardiovascular disease (147)
Career advice (3533)
Career pathing (34)
CAR-T (165)
Cell therapy (461)
Cervical cancer (18)
Clinical research (72924)
Collaboration (803)
Company closure (2)
Compensation (474)
Complete response letters (28)
COVID-19 (2834)
CRISPR (46)
C-suite (233)
Cystic fibrosis (100)
Data (1955)
Decentralized trials (2)
Denatured (46)
Depression (40)
Diabetes (190)
Diagnostics (6768)
Digital health (9)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (118)
Drug pricing (97)
Drug shortages (17)
Duchenne muscular dystrophy (85)
Earnings (95632)
Editorial (38)
Employer branding (25)
Employer resources (167)
Events (128773)
Executive appointments (630)
FDA (19037)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (662)
Gene editing (106)
Generative AI (22)
Gene therapy (327)
GLP-1 (740)
Government (5117)
Grass and pollen (4)
Guidances (95)
Healthcare (20744)
Huntington's disease (26)
IgA nephropathy (29)
Immunology and inflammation (133)
Indications (25)
Infectious disease (2952)
Inflammatory bowel disease (157)
Inflation Reduction Act (11)
Influenza (45)
Intellectual property (86)
Interviews (813)
IPO (17703)
IRA (38)
Job creations (5189)
Job search strategy (2861)
Kidney cancer (11)
Labor market (45)
Layoffs (550)
Leadership (22)
Legal (10057)
Liver cancer (73)
Lung cancer (298)
Lymphoma (140)
Machine learning (6)
Management (65)
Manufacturing (307)
MASH (74)
Medical device (14301)
Medtech (14306)
Mergers & acquisitions (22291)
Metabolic disorders (609)
Multiple sclerosis (80)
NASH (22)
Neurodegenerative disease (104)
Neuropsychiatric disorders (23)
Neuroscience (1988)
NextGen: Class of 2025 (7666)
Non-profit (5058)
Now hiring (41)
Obesity (325)
Opinion (271)
Ovarian cancer (70)
Pain (74)
Pancreatic cancer (67)
Parkinson's disease (135)
Partnered (19)
Patents (202)
Patient recruitment (99)
Peanut (48)
People (64951)
Pharmaceutical (131)
Pharmacy benefit managers (14)
Phase I (22538)
Phase II (31719)
Phase III (23823)
Pipeline (1141)
Policy (149)
Postmarket research (3542)
Preclinical (10164)
Press Release (72)
Prostate cancer (91)
Psychedelics (34)
Radiopharmaceuticals (251)
Rare diseases (365)
Real estate (7384)
Recruiting (75)
Regulatory (26480)
Reports (56)
Research institute (2647)
Resumes & cover letters (649)
Rett syndrome (2)
RNA editing (5)
RSV (34)
Schizophrenia (72)
Series A (127)
Series B (75)
Service/supplier (25)
Sickle cell disease (47)
Special edition (19)
Spinal muscular atrophy (164)
Sponsored (34)
Startups (4287)
State (2)
Stomach cancer (11)
Supply chain (51)
Tariffs (43)
The Weekly (83)
Vaccines (745)
Venture capitalists (42)
Weight loss (229)
Women's health (37)
Worklife (20)
Date
Today (186)
Last 7 days (748)
Last 30 days (2490)
Last 365 days (28492)
2025 (9612)
2024 (34030)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Alabama (54)
Alaska (6)
Arizona (247)
Arkansas (8)
Asia (49891)
Australia (8803)
California (5540)
Canada (1611)
China (510)
Colorado (171)
Connecticut (220)
Delaware (139)
Europe (114224)
Florida (694)
Georgia (151)
Hawaii (1)
Idaho (64)
Illinois (452)
India (25)
Indiana (277)
Iowa (10)
Japan (143)
Kansas (112)
Kentucky (16)
Louisiana (9)
Maine (58)
Maryland (862)
Massachusetts (4348)
Michigan (187)
Minnesota (316)
Mississippi (1)
Missouri (53)
Montana (24)
Nebraska (26)
Nevada (58)
New Hampshire (50)
New Jersey (1571)
New Mexico (27)
New York (1554)
North Carolina (1022)
North Dakota (8)
Northern California (2440)
Ohio (167)
Oklahoma (13)
Oregon (45)
Pennsylvania (1164)
Puerto Rico (13)
Rhode Island (24)
South America (1649)
South Carolina (5)
South Dakota (1)
Southern California (2076)
Tennessee (30)
Texas (731)
United States (20619)
Utah (118)
Virginia (106)
Washington D.C. (41)
Washington State (524)
West Virginia (1)
Wisconsin (43)
839,964 Results for "exai bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.
April 8, 2024
·
4 min read
Press Releases
Exai Bio Appoints Oncology Leader and Former American Cancer Society CEO, Karen E. Knudsen, MBA, PhD, to its Board of Directors
December 5, 2024
·
2 min read
Biotech Bay
Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy, Overcoming Many Limitations of DNA-based Approaches
Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample.
December 6, 2023
·
3 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Biotech Bay
Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer
Exai Bio announced non-small cell lung cancer data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.
September 12, 2023
·
4 min read
Biotech Bay
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
Exai Bio announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ to broaden the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ treatment response and disease burden in the I-SPY 2 TRIAL.
March 30, 2023
·
5 min read
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
·
2 min read
·
Dan Samorodnitsky
Biotech Bay
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
June 3, 2023
·
4 min read
Biotech Bay
Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages
Researchers at Exai Bio and UCSF have released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and for the smallest tumors.
December 6, 2022
·
3 min read
Biotech Bay
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts.
April 18, 2023
·
3 min read
1 of 83,997
Next
